{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypothyroidism/management/postpartum/","result":{"pageContext":{"chapter":{"id":"611f3939-9d39-5545-b225-f9b33fdb095e","slug":"postpartum","fullItemName":"Scenario: Postpartum","depth":2,"htmlHeader":"<!-- begin field dd42c7de-ee0c-4360-b991-b1ceb24ed0c1 --><h2>Scenario: Postpartum</h2><!-- end field dd42c7de-ee0c-4360-b991-b1ceb24ed0c1 -->","summary":"Covers the management of postpartum women with subclinical hypothyroidism, overt hypothyroidism, or postpartum thyroiditis.","htmlStringContent":"<!-- begin item 90ffaa2d-9eaa-435d-a440-b55b94aa7836 --><!-- begin field bcb5d5ff-b103-4300-9279-acbc01564678 --><p>From age 18 years onwards (Female).</p><!-- end field bcb5d5ff-b103-4300-9279-acbc01564678 --><!-- end item 90ffaa2d-9eaa-435d-a440-b55b94aa7836 -->","topic":{"id":"f1d76bc1-c8dd-515b-a709-48c70c829658","topicId":"ebfc5032-6653-4b11-895c-5080f933e861","topicName":"Hypothyroidism","slug":"hypothyroidism","lastRevised":"Last revised in August 2020","chapters":[{"id":"cf0a606b-f582-5671-a84d-a1a3a12b7180","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"795eb9d9-4e15-51f6-81f4-7cc1b69ca74e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a8d7a846-dfa6-5db5-ba95-fb161fd48c6e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d8567cc1-0642-5e9e-ad6c-8ca4abf5fa6e","slug":"changes","fullItemName":"Changes"},{"id":"c5e99cd1-e0c7-5efd-84bb-15bac6122b1d","slug":"update","fullItemName":"Update"}]},{"id":"2b8464ae-3182-517a-85be-6acc656616c5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"17d5ebf3-bdca-50d2-a4f5-245d191f4973","slug":"goals","fullItemName":"Goals"},{"id":"9162c6a3-edc4-5319-9418-04b2cb656ce6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2ae5c1d9-638e-52fa-b738-9561cd11b0ab","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7fec82ae-e144-56a7-b1e8-8744c35e227e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"610f052f-83a2-5b06-b5e6-4aa272ef73a6","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a578bde3-0d84-54f7-814d-18ed38e6038a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"66bb9b4f-4de2-5da7-aba1-ec9bff4b2454","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"4b8f382f-673d-5804-8291-438e21e32790","slug":"definition","fullItemName":"Definition"},{"id":"ef0d96cd-207c-5814-93cf-c96870e2251d","slug":"causes","fullItemName":"Causes"},{"id":"09adb285-1d01-592a-9443-295b45c7d78b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9bfb88d8-8d33-53a3-8d0e-1b202457fb2e","slug":"complications","fullItemName":"Complications"},{"id":"5ff1ef9f-bb77-5feb-bd5a-12d7b43cca9d","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"cfe582c4-479a-5d44-b893-ac46a1a80b29","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6884c3db-6165-566b-a4ca-3e933de77714","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"42799fb8-7252-541e-9af1-27ebc28710b7","slug":"assessment","fullItemName":"Assessment"},{"id":"e850b740-b6cf-55a7-aed8-7372b7f13b05","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"d817ab4c-e7a3-582a-94fa-fcffd9c2d4f6","slug":"screening","fullItemName":"Screening"}]},{"id":"b377a2c4-68d7-573f-912f-123b99d0aba1","fullItemName":"Management","slug":"management","subChapters":[{"id":"daacd844-c78f-5626-a2ea-93077f98f729","slug":"overt-hypothyroidism-non-pregnant","fullItemName":"Scenario: Overt hypothyroidism (non-pregnant)"},{"id":"e358d249-a2f3-5a06-b301-2119af9ae164","slug":"subclinical-hypothyroidism-non-pregnant","fullItemName":"Scenario: Subclinical hypothyroidism (non-pregnant)"},{"id":"9e4d552e-5fb3-571b-b14a-fec340b943f0","slug":"preconception-or-pregnant","fullItemName":"Scenario: Preconception or pregnant"},{"id":"611f3939-9d39-5545-b225-f9b33fdb095e","slug":"postpartum","fullItemName":"Scenario: Postpartum"}]},{"id":"7b2d6d51-4029-5c06-8789-30e0056076fa","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"ee5ac1fb-6ba7-5e52-9861-d62637c03bf0","slug":"levothyroxine","fullItemName":"Levothyroxine"}]},{"id":"2aaf1754-ba79-5b47-b2a5-74fe8f6af4da","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7669c894-3a85-55c7-b689-cb4b710a838a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"840d7de5-8c31-5696-9de6-c80ce1bbfec7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"299c20bf-2a22-5681-99ad-5f02f1395969","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"dd3df39b-4a5c-5416-af8d-dcdbf46bd255","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a88d4431-778a-5793-9557-9f806339a95b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1987302d-f600-55e0-a528-d3486c49048e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a49e5d2f-75e4-5219-a4d6-fd4a5595a776","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b377a2c4-68d7-573f-912f-123b99d0aba1","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"ade06994-601a-5587-b9e2-d04231beb099","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 23033dfd-1ab3-4fa2-9ee8-f251914dd0d8 --><h3>How should I manage a woman who is postpartum?</h3><!-- end field 23033dfd-1ab3-4fa2-9ee8-f251914dd0d8 -->","summary":null,"htmlStringContent":"<!-- begin item 9f604f64-5471-46ae-8527-d1cd140ab83a --><!-- begin field 8b86a9e1-4ace-4cb9-a5d8-ba02571ee1a3 --><ul><li><strong>If a woman has been treated with levothyroxine (LT4) for overt or subclinical hypothyroidism in pregnancy:</strong><ul><li>Discuss with an endocrinologist what changes to LT4 dose and frequency of thyroid function test (TFT) monitoring is needed postpartum, if specialist advice has not already been given to the woman following delivery.<ul><li>For many women following delivery, the LT4 dose should be reduced to pre-pregnancy levels, and a serum thyroid-stimulating hormone (TSH) level should be checked after 6 weeks.</li></ul></li></ul></li><li><strong>If a woman has been diagnosed with <a class=\"topic-reference internal-reference\" href=\"/topics/hypothyroidism/background-information/causes/\">postpartum thyroiditis</a> (PPT):</strong><ul><li>If initial TFTs show a thyrotoxic pattern:<ul><li>Refer to an endocrinology specialist, the urgency depending on clinical judgement, to differentiate suspected PPT from Graves’ disease and to advise on ongoing management. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hyperthyroidism/\">Hyperthyroidism</a> for more information.</li><li>Check TFTs 4–8 weeks after resolution of the thyrotoxic phase, to screen for the hypothyroid phase (or sooner if symptoms develop).</li></ul></li><li>If TFTs show a hypothyroid pattern, discuss with an endocrinologist whether to start LT4 treatment in primary care and the frequency of TFT monitoring needed. In general:<ul><li>Symptomatic women, women who are breastfeeding, and those planning another pregnancy should be treated with LT4.</li><li>Untreated asymptomatic women who are not planning a pregnancy should be reassessed in 4–8 weeks, and if the TSH remains above the reference range, a specialist may start treatment with LT4.</li><li>Untreated asymptomatic women should have their TFTs checked every 4–8 weeks until thyroid function normalizes.</li></ul></li><li>Following resolution of PPT, arrange annual TFT monitoring.</li></ul></li></ul><!-- end field 8b86a9e1-4ace-4cb9-a5d8-ba02571ee1a3 --><!-- end item 9f604f64-5471-46ae-8527-d1cd140ab83a -->","subChapters":[{"id":"77d47950-2387-5339-9235-7843c85e3e04","slug":"basis-for-recommendation-491","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6fd3363d-99a2-47b6-b8e3-b47eabfc599c --><h4>Basis for recommendation</h4><!-- end field 6fd3363d-99a2-47b6-b8e3-b47eabfc599c -->","summary":null,"htmlStringContent":"<!-- begin item 491c9575-5cc4-4454-9074-5a5090298d52 --><!-- begin field 9198258e-184a-4ec3-9576-2236986f518b --><p>The recommendations on management of subclinical or overt hypothyroidism in the postpartum period are based on the joint UK publication <em>UK guidelines for the use of thyroid function tests</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Association for Clinical Biochemisty, 2006</a>], the European Thyroid Association (ETA) <em>Guidelines for the management of subclinical hypothyroidism in pregnancy and in children</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Lazarus et al, 2014</a>], the American Thyroid Association (ATA) <em>Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>], and the Endocrine Society clinical practice guideline <em>Management of thyroid dysfunction during pregnancy and postpartum</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">De Groot et al, 2012</a>].</p><h5>Advice on levothyroxine (LT4) dose changes following delivery</h5><ul><li>The information that most women with hypothyroidism will need to decrease the LT4 dose they receive during pregnancy to pre-pregnancy levels is based on the Endocrine Society clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">De Groot et al, 2012</a>] and the ETA guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Lazarus et al, 2014</a>].</li><li>This is supported by the ATA guidelines which note that following delivery, the maternal LT4 dose should be reduced to pre-pregnancy levels, and a serum thyroid-stimulating hormone (TSH) level should be checked after six weeks. The guideline notes, however, that some women with Hashimoto’s thyroiditis require an increase in the pre-pregnancy thyroid hormone dose in the postpartum period, presumably due to an exacerbation of autoimmune thyroid dysfunction post-delivery [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>].</li><li>The ETA guidelines suggest that women diagnosed with subclinical hypothyroidism during pregnancy with a TSH level less than 5 mU/L and negative thyroid peroxidase antibodies (TPOAbs) could stop LT4 after delivery, and have TFTs checked six weeks after delivery [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Lazarus et al, 2014</a>].</li></ul><h5>Advice for women with postpartum thyroiditis (PPT)</h5><ul><li>The ATA guidelines provide advice on monitoring of TFTs after resolution of the thyrotoxic phase of PPT [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">Alexander, 2017</a>].</li><li>The Endocrine Society clinical practice guideline notes that women with a history of PPT are at increased risk of developing permanent primary hypothyroidism within 5–10 years of the episode of PPT [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypothyroidism/references/\">De Groot et al, 2012</a>].</li></ul><!-- end field 9198258e-184a-4ec3-9576-2236986f518b --><!-- end item 491c9575-5cc4-4454-9074-5a5090298d52 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}